mynth
01/2026MajorityLBO

Antin Infrastructure takes majority stake in Emsere

NETHERLANDS Healthcare Services / CRO / Clinical Trials REV 1m EUR - 100m EUR

Context

Antin Infrastructure Partners, executing through its Mid Cap Fund I, has entered into a definitive agreement with Dutch family office and investment platform Gryphion to acquire 100% of Emsere. The transaction, which represents the eighth investment completed by Antin's dedicated mid-cap vehicle, is scheduled to close in the first quarter of 2026. The corporate buyouts' advisory perimeter included Macquarie as financial adviser and Loyens & Loeff as legal adviser to Antin, while Gryphion was backed by Moelis as financial adviser and DLA Piper as legal adviser. The acquisition thesis frames the clinical trial equipment rental space as an institutional healthcare infrastructure play, characterized by favorable long-term macroeconomic trends and high structural barriers to entry. The strategic rationale centers on capitalizing on the rapid growth of innovative clinical research endpoints, which drive outsourcing demands and require highly complex, specialized medical equipment and lifecycle service solutions.

The acquisition of Emsere is part of the growth strategy of Antin Infrastructure, which already has several external growth operations under its belt, notably Swiftair Group in 2025.

Emsere, which reported an EBITDA margin of [members only] in 2026, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Emsere is a global leader in clinical trial equipment rental, providing mission-critical medical equipment and specialized logistics solutions for contract research organizations and pharmaceutical companies worldwide. Founded in 1996, Emsere is headquartered in Leiden, the Netherlands, and offers a comprehensive range of medical equipment, including centrifuges, vital signs devices, cardiovascular and respiratory monitoring machines, imaging devices, and cardio-pulmonary exercise testing equipment. With over 13,000 pieces of equipment in its portfolio, Emsere delivers to over 100 countries through its own distribution centers and third-party relationships, making it a globally consolidated solution for all clinical trial equipment needs. Emsere's customers include six of the top 10 global pharmaceutical companies and seven of the top 10 contract research organizations globally. Emsere is well-positioned in the fast-growing clinical trial equipment rental market, which continues to expand driven by increasing demand for outsourcing and the growing need for more complex equipment and service solutions to keep pace with innovative and evolving clinical research endpoints.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2026
€1–100M
[members only]
[members only]
2025
€1–100M
[members only]
[members only]

Other operations with Antin Infrastructure

Other operations with Antin Infrastructure
DateAcquirerTargetCountrySector
10/2026ANTIN INFRASTRUCTUREHIGH PERFORMANCE HELICOPTERSUNITED STATESAir Freight
02/2026ANTIN INFRASTRUCTUREBELAMBRA CLUBSFRANCEHotels & Accommodation
10/2025ANTIN INFRASTRUCTURESWIFTAIR GROUPSPAINAir Freight
08/2023ANTIN INFRASTRUCTURECONSILIUM SAFETY GROUPSWEDENSafety & Security
06/2023ANTIN INFRASTRUCTUREOPDENERGYSPAINSolar / PV
12/2020ANTIN INFRASTRUCTUREHIPPOCRATES (LAF - LA FARMACIA)ITALYPharmacy
09/2020ANTIN INFRASTRUCTUREMIYA WATERSPAINWater
08/2020ANTIN INFRASTRUCTUREBABILOU FAMILYFRANCEEducation Providers
07/2019ANTIN INFRASTRUCTUREVICINITY ENERGYUNITED STATESDistrict Heating
05/2018ANTIN INFRASTRUCTUREIDEXFRANCEDistrict Heating

Similar deals in Healthcare Services

Similar deals in Healthcare Services
DateAcquirerTargetCountrySector
03/2026THERMO FISHER SCIENTIFICCLARIO HOLDINGSUNITED STATESCRO / Clinical Trials
03/2026RADNETGLEAMERFRANCEHealth Tech
01/2026SAGARDQUIPMENTFRANCEHealthcare Services
01/2026PERMIRACARNE GROUPIRELANDHealthcare Services
01/2026TPGOPTUM UKUNITED KINGDOMHealth Tech
12/2025PHARMA EQUITY GROUPOTIOMDENMARKHealth Tech
11/2025EURAZEOEXCELYAFRANCECRO / Clinical Trials
11/2025ASKER HEALTHCARE GROUPFINMED GROUPFRANCEHospital Logistics
10/2025EVOLEMAPPERTONFRANCESterilization & Hygiene
05/2025FIVE ARROWSHUBLOFRANCEHealth Tech

REFERENCES

Revenue range: REV 1m EUR - 100m EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Emsere by Antin Infrastructure are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: emsere

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Emsere, a Dutch company specialised in CRO / Clinical Trials, by Antin Infrastructure in 2026, structured as a leveraged buyout (LBO).

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.